Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.85 per share in cash. The price represents a 27% premium to the 90-day volume-weighted average price of $4.61 ...

Nevro (NVRO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

Estimate Trend Nevro has been witnessing a negative estimate revision trend for 2025. In the past 30 days, the Zacks Consensus Estimate for its loss per share has expanded 16 cents to $2.67.

Nevro also published guidance for the first quarter and the year. For 2024, it's expecting revenue in the range of $435 million to $445 million. This would shake out to growth of 2% to 5%.